Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.

[1]  W. Evans,et al.  Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission‐induction therapy , 1987, Clinical pharmacology and therapeutics.

[2]  C. Ou,et al.  Simultaneous measurement of ethosuximide, primidone, phenobarbital, phenytoin, carbamazepine, and their bioactive metabolites by liquid chromatography. , 1984, Clinical chemistry.

[3]  M. Lobell,et al.  Impaired Phenytoin Bioavailability Secondary to Cisplatinum, Vinblastine, and Bleomycin , 1984, Therapeutic drug monitoring.

[4]  L. J. Fischer,et al.  Phenytoin and Folic Acid Interaction: A Preliminary Report , 1983, Therapeutic drug monitoring.

[5]  P. MacCosbe,et al.  Interaction of phenytoin and folic acid. , 1983, Clinical pharmacy.

[6]  A. Pesce,et al.  Free drug concentrations are constant in serial fractions of plasma ultrafiltrate. , 1982, Clinical chemistry.

[7]  B. Chabner.  Pharmacologic principles of cancer treatment , 1982 .

[8]  Fincham Rw,et al.  Decreased phenytoin levels in antineoplastic therapy. , 1979 .

[9]  Parish Lc.  Letter: Postoperative wound infections and hair carriers. , 1974 .

[10]  J. Maxwell,et al.  Folate Deficiency after Anticonvulsant Drugs: An Effect of Hepatic Enzyme Induction? , 1972, British medical journal.

[11]  J. Preece,et al.  Influence of folic acid on blood-phenytoin levels. , 1971, Lancet.

[12]  F. Mcdowell,et al.  Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy , 1966, Neurology.